I Found Something Kamala Is Good at and It's a Problem
Biden Demands More Gun Control After SCOTUS Shoots Down the Administrative State
It's Time to Crush Our Opponents
The DOJ Says It 'Determined' Attorney General Merrick Garland Is Innocent
The Latest Case of a CCP-Linked Individual Threatening America's Economic Interests, Natio...
Ingraham: If Trump Wins, MAGA Coalition Could Be in Power for Decades
The Importance of Miracles
Here's Another Joe Biden Senior Moment For the Books
Trump's Latest Proposal Could Earn Him Big Points With Blue-Collar Workers
Pete Hegseth's 'The War on Warriors' Tops Bestsellers List, While Jen Psaki Continues...
Judge Blocks Biden's Updated Title IX Regulations in Four States
House Passes NDAA With Key Pro-Life Provisions
Lia Thomas' Former Teammate Weighs in After He Is Banned From Competing in...
Expect to Keep Hearing This Democratic Talking Point After New Poll
'Sit Down': AOC Called Out for Condemning Pro-Hamas Protests
Tipsheet

A New Non-mRNA Covid-19 Vaccine Just Cleared a Major Hurdle to Becoming Next Authorized Jab

AP Photo/Alastair Grant, File

The Food and Drug Administration advisory committee has recommended the agency give the green light to Novavax’s Covid-19 vaccine, which offers a more traditional, non-mRNA alternative to the Pfizer and Moderna shots. 

Advertisement

The FDA’s Vaccines and Related Biological Products Committee voted 21-0, with one abstention, to recommend the vaccine for emergency use authorization. 

"The Advisory Committee's positive recommendation acknowledges the strength of our data and the importance of a protein-based COVID-19 vaccine developed using an innovative approach to traditional vaccine technology," Novavax president and CEO Stanley Erck said Tuesday.

“We have heard in today’s VRBPAC meeting the significant support for our vaccine from physicians, healthcare organizations, and consumers who are eagerly anticipating a protein-based vaccine option,” he added. 

The data Novavax presented to the committee showed the vaccine was 90 percent effective in preventing mild and severe Covid-19, although the two large clinical trials were conducted before the Omicron wave. Additionally, the vaccine had a "reassuring safety profile," the company said. 

Erck said there is a market for the company in the U.S. among the "tens of millions of people who have not had their primary vaccine for one reason or another." Additionally, other potential markets include children and those who need booster shots.


"We do have a problem with vaccine uptake that is very serious in the United States, and anything we can do to get people more comfortable to be able to accept these potentially life-saving medical products is something that we feel we are compelled to do," said Dr. Peter Marks, director of the Center for Biologics Evaluation and Research. 
Dr. Eric Rubin, editor-in-chief of the New England Journal of Medicine and a member of VRBPAC, asked in the meeting why there is a need for another Covid-19 vaccine in the United States when three have been authorized or approved: those from Pfizer/BioNTech, Moderna and Johnson & Johnson's Janssen.
"The Janssen vaccine is currently not being used as a frontline vaccine the same way as the mRNA vaccines, which leaves the issue of vaccines for those who might not want to take an mRNA vaccine because of concerns they might have," Marks responded, referring to the vaccines developed by Pfizer/BioNTech and Moderna.
"Having a protein-based alternative may be more comfortable for some in terms of their acceptance of vaccine," Marks said. (CNN)
Advertisement

Novavax's Covid-19 shot is currently available in more than 40 countries. 

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement